If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Where in the body are the GIP receptors to which Mounjaro® (tirzepatide) binds?
There is no information on which GIP receptors are bound by tirzepatide in the human body.
See important safety information, including boxed warning, in the attached prescribing information.
Location of GIP Receptors That Bind to Tirzepatide
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
There is currently no data available to indicate which GIP receptors in the human body bind to tirzepatide.
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: March 21, 2023